.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
Teva
Boehringer Ingelheim
Farmers Insurance
Chubb
Fuji
Dow
Queensland Health
Healthtrust

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,709,446

« Back to Dashboard

Which drugs does patent 6,709,446 protect, and when does it expire?


Patent 6,709,446 protects LEVULAN and is included in one NDA.

This patent has twenty-eight patent family members in twenty countries.

Summary for Patent: 6,709,446

Title: Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
Abstract:An apparatus and method for photodynamic therapy or photodynamic diagnosis using an illuminator comprising a plurality of light sources generally conforming to a contoured surface and irradiating the contoured surface with substantially uniform intensity visible light. The light sources may comprise generally U-shaped fluorescent tubes that are driven by electronic ballasts. Adjustment of the ballast voltage controls the output power of the tubes. The tubes are supported by a sheet-metal or plastic housing and are covered by a polycarbonate shield which directs cooling airflow within the unit and prevents glass-patient contact in the event of tube breakage. An aluminum reflector located behind the tubes increases both the output irradiance and the uniformity of the output distribution. The spacing of the U-shaped tubes is varied to increase the output at the edges of the illuminator to make the output more uniform. Also, different portions of the tubes are cooled at different amounts, to improve uniformity. A light sensor monitors output from the U-shaped tubes to provide a signal for adjusting the output from the tubes.
Inventor(s): Lundahl; Scott (Lexington, MA), Kozodoy; Rebecca (Randolph, MA), Carroll; Ronald (Hingham, MA), Leppelmeier; Elton (Highland Height, OH)
Assignee: Dusa Pharmaceuticals, Inc. (Toronto, CA)
Application Number:09/774,084
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Dusa
LEVULAN
aminolevulinic acid hydrochloride
SOLUTION;TOPICAL020965-001Dec 3, 1999RXYesYes► Subscribe► Subscribe TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,709,446

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,223,071 Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light► Subscribe
8,030,836Illuminator for photodynamic therapy► Subscribe
8,216,289Illuminator for photodynamic therapy► Subscribe
9,723,991Illuminator for photodynamic therapy► Subscribe
8,758,418Illuminator for photodynamic therapy► Subscribe
7,723,910Method of photodynamically diagnosing or treating a contoured surface► Subscribe
7,190,109Illuminator for photodynamic therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,709,446

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany69922944► Subscribe
Canada2331090► Subscribe
China1308553► Subscribe
Czech Republic20004038► Subscribe
Czech Republic298928► Subscribe
Germany69940488► Subscribe
Denmark1075315► Subscribe
Denmark1566200► Subscribe
European Patent Office1075315► Subscribe
European Patent Office1510233► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Daiichi Sankyo
Colorcon
Citi
QuintilesIMS
Federal Trade Commission
Express Scripts
Novartis
Cantor Fitzgerald
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot